Alpelisib
This page contains brief information about alpelisib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Vijoice
FDA label information for this drug is available at DailyMed.
Use in Cancer
Alpelisib is approved to treat:
- Breast cancer that is hormone receptor positive and HER2 negative and has a mutation in the PIK3CA gene. It is used with fulvestrant to treat postmenopausal women, and men, whose breast cancer has spread and has gotten worse during or after treatment with hormone therapy.
Alpelisib is also being studied in the treatment of other types of cancer.
More About Alpelisib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Alpelisib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Alpelisib - Check for trials from NCI's list of cancer clinical trials now accepting patients.